1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Rheumatoid Arthritis Data Position Filgotinib Ahead Of Competition, But It's Playing Catch-Up

 
• By Sten Stovall

Prospects rose for Galapagos and partner Gilead's JAK1 inhibitor with impressive Phase III FINCH 2 data in patients with moderate-to-severe rheumatoid arthritis. 

Rheumatoid Arthritis
Pivotal FINCH 2 Trial Gave Impressive Top-line Data In Rheumatoid Arthritis • Source: Shutterstock

More evidence supporting Gilead Sciences Inc. and its partner Galapagos NV's jointly developed JAK1 selective kinase inhibitor has come in the form of positive results from filgotinib's first pivotal trial in rheumatoid arthritis - results that analysts say effectively de-risk the investigational therapy.

Filgotinib, which is being developed for multiple indications, achieved the primary endpoint in the FINCH 2 late-stage study evaluating it in doses of 100 mg and 200 mg versus placebo in adults with moderately to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

More from R&D

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.